GPP
XENE icon

Great Point Partners’s Xenon Pharmaceuticals XENE Stock Holding History

Great Point Partners’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,700
Closed -$104K – 54
2023
Q2 		$104K Buy
+2,700
New +$107K 0.02% 40

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Great Point Partners's XENE Position: Q4 2025 in Review

Great Point Partners sold out of Xenon Pharmaceuticals (XENE) in Q4 2025, closing a stake of 200,000 shares — an estimated $8.03M sold.

Great Point Partners first reported a position in XENE in Q3 2021 and held it in 15 quarters. The position peaked at $33.6M in Q2 2022. 246 funds tracked by Wall St. Rank hold XENE as of Q4 2025.

  • Great Point Partners reported no remaining Xenon Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Great Point Partners sold 200,000 Xenon Pharmaceuticals shares in Q4 2025, an estimated $8.03M.
  • Great Point Partners first reported a position in Xenon Pharmaceuticals in Q3 2021 and held it in 15 quarters.
  • Great Point Partners's Xenon Pharmaceuticals position peaked at $33.6M in Q2 2022.
  • 246 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2025.

Based on Great Point Partners's 13F filing for Q4 2025, filed 17 Feb 2026.